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A significant amount of effort has been put into the research and development of 
peptide-based drugs for the treatment of human disease.  The use of anticonvulsant 
neuropeptides for the treatment of pain and epilepsy has recently shown promise.  
Neuropeptides such as galanin (Gal), neuropeptide Y (NPY), neurotensin (NT), and 
neuropeptide W (NPW) modulate their biological activities through their respective 
receptor targets in the brain.  Introduced intracerebroventricularly, these compounds have 
been shown to reduce pain and seizure activity.  Upon systemic administration, however, 
these compounds do not exhibit the same potency.  The metabolic instability and inability 
to penetrate the blood-brain barrier (BBB) has precluded their widespread use as drugs 
for neurological disorders.    This work will describe the application of the lipidization-
cationization strategy to several endogenous neuropeptides towards increasing their 
metabolic stability and improving systemic bioavailability.  Based on existing structure 
activity relationship (SAR) information, analogs of Gal, NPY NT, and NPW were 
designed and chemically synthesized.  The combination of increased cationic character 
(oligo-Lys motifs) and increased lipophilicity (lipoamino acid) resulted in analogs with 
increased octanol-water partitioning coefficients (logD), significantly improved 
metabolic stabilities, while retaining high affinities for their native receptors.  
Furthermore, these analogs were shown to modulate seizure activity in animal models of 
epilepsy upon systemic administration.  Our results suggest that the cationization-
lipidization strategy may be broadly applicable across a wide variety of neuropeptides, 
opening up a large repertoire of new drug candidates for the treatment of neurological 
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1.1 Literature Review 
1.1.1 Past and Present Treatments for Pain and Epilepsy 
 Excessive, uncontrolled firing of neurons (hyperexcitability) in the central 
nervous system (CNS) or peripheral nervous system (PNS) may result in a number of 
different neurological disorders.  Hyperexcitability is often caused by decreased amounts 
of the anticonvulsant compound gamma-aminobutyric acid (GABA), or through 
disruptions in the cellular machinery responsible for maintaining Na+/Ca2+ homeostasis 
(1).  If localized to the brain, individuals may suffer from seizure.  Hyperexcitability in 
neurons associated with the spinal cord may result in painful neuropathies.  As the 
underlying mechanisms of seizure activity and neuropathic pain are similar, the 
approaches taken towards treatment are often overlapping.  For example, numerous first 
and second-generation anticonvulsant compounds, such as lamotrigine and gabapentin, 
have shown promise in treating neuropathic pain (1).   
Neuropathic pain is a form of pain that can arise either from insult to the 
CNS/PNS, or by dysfunction of the nerve itself caused by illness or by the treatment of 
some illnesses (e.g., chemotherapy).  Since neuropathic pain is not characterized as a 
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single disease, rather a spectrum of disorders all resulting in similar outcomes, treatment 
of neuropathies has been difficult (2).  Of the analgesic compounds used for the treatment 
of acute pain, whether opioid or nonopioid, many have proven ineffective in alleviating 
some forms of neuropathic pain (3).  It is estimated neuropathic pain affects 
approximately 1.5% of the total world population (4).  Additionally, of this fraction of the 
population affected by neuropathic pain, only about one-third of people respond to 
currently available treatments (2).  The most common treatment of neuropathic pain has 
been the administration of opioid-based drugs.  However, opioids possess a number of 
undesirable side effects, including tolerance, constipation, high rates of abuse, respiratory 
depression, etc. (2).  Aside from opioid-based drugs, antidepressants, anticonvulsants, N-
methyl-D-aspartic acid (NMDA) receptor antagonists, and cannabinoids have also been 
explored (2).  Despite the effectiveness of some of these approaches, the search continues 
for analgesic compounds with increased specificity, improved efficacy, and lower 
toxicity for the treatment of painful neuropathies. 
Epilepsy is broadly classified as the occurrence of unprovoked seizures.  Similar 
to what is observed in neuropathic pain, seizures commonly result from hyperexcitability 
of neurons.  Affecting nearly 50 million individuals worldwide, epilepsy is the second 
most common neurological disorder, second only to stroke (5).  In developed countries, it 
is estimated that epilepsy affects approximately 50 out of 100,000 people per year (6, 7).   
The earliest antiepileptic drug (AED), potassium bromide, was reported in 1857 
by Sir Charles Locock (8).  The next advance in the generation of AEDs came in 1912 
when Albert Hauptmann recommended the use of barbiturates (phenobarbital) to 
suppress seizure activity (8).  Through the use of animal models of epilepsy, Merritt and 
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Putnam discovered the antiepileptic properties of phenytoin in 1938.  This compound 
showed promise in treating seizures in individuals that did not respond to either 
potassium bromide or phenobarbital.  However, phenytoin was later found to exhibit 
several undesirable properties including toxicity, carcinogenicity, unpredictable 
pharmacokinetics and adverse drug interactions (8).  The next development in 
antiepileptic drug discovery came in 1963 with the description of the anticonvulsant 
properties of carbamazepine (CBZ) by Lorge and coworkers.  CBZ had been found to be 
the most effective compound for suppression of partial seizure.  As with previous AEDs 
side effects were discovered including: rash, blood toxicity, thrombosytopenia and 
Stevens-Johnson syndrome (8).   Shortly after discovery of CBZ, valproate acid was 
characterized.  Valproate was found to be efficacious against a wide range of epilepsies 
including idiopathic and symptomatic epilepsy.  Nearly a quarter-century after the 
discovery of CBZ (1989), vigabatrin, the first of many next-generation AEDs was 
developed.  This compound acted to selectively inhibit the enzyme responsible for 
breaking down gamma aminobutyric acid (GABA) (8).  GABA serves to modulate 
neuronal excitability; as such, compounds that prevent the metabolism of GABA may 
dampen excitatory behaviors like those observed in seizure.  The following 20 years of 
AED research resulted in a number of compounds that inhibited epileptic seizure by 
targeting the GABAergic system or by modulating ion flow in specific ion channels.  To 
date, there are 20 compounds approved by the U.S. Food and Drug Administration for the 
treatment of epileptic seizure. 
Though epilepsy is generally considered treatable using currently available AEDs, 
a significant portion of the patient population will either develop drug resistance or will 
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be completely unresponsive to AED treatments (pharmacoresistant epilepsy).  
Additionally, most of the currently prescribed AEDs exhibit cognitive impairment as a 
common side effect.  It is estimated, that of the total number of those who suffer from 
active epilepsy, nearly 30% will not respond to available drug treatments (9).  As 
alternatives to drug treatment for the control of seizure activity, patients are relegated to 
more invasive therapies such as implantable stimulation devices or resection of affected 
brain tissues (10).   In light of pharmacoresistant epilepsy, it is apparent that there is still 
an unmet need for alternative treatments for controlling seizures. 
 
1.1.2 Advantages of Peptide-Based Drugs as First-In-Class Therapies 
Alternative drug treatments are currently being explored due to the lack of 
receptor specificity of current drugs in treating neuropathic pain, or the inability to 
effectively treat a significant population of people suffering from pharmacoresistant 
epilepsy.  Our group has sought to treat pain and/or epilepsy using a peptide-based drug 
approach.  There are numerous advantages of peptide-based drugs over their small 
molecule counterparts.  First, peptides are extremely specific ligands for their molecular 
targets, and as a result, show less of the off-target effects exhibited by many small 
molecule drugs (11).  Second, the structural and chemical diversity of synthetic peptides 
has drastically increased since the advent of solid phase peptide synthesis (SPPS) by 
Merrifield in 1963 (12).  Beyond the naturally-occurring 20 amino acid repertoire 
available through recombinant methods, SPPS has provided the incorporation of 
numerous non-natural amino acids including glycoamino acids, backbone spacer units, 
fluorescent markers, lipoamino acids, and others.  In addition to increasing the potential 
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for structural diversity amongst synthetic peptides, the advent of SPPS also increased the 
ease of synthesis of these compounds as amino acid building blocks are incorporated 
through repeated dehydration reactions using Fmoc or Boc chemistries. Finally, peptides 
are attractive drug candidates because of their low toxicity profiles (11).  It is well known 
that peptides and proteins are biodegraded into smaller cleavage products, or even into 
individual amino acids for use in synthesis of new biomolecules or for excretion.  As 
such, peptide-based drugs present attractive therapeutics because the metabolites of such 
compounds may either be used directly or removed completely from the system (13, 14).   
 
1.1.3 Hurdles in the Development of Peptides as Therapeutics 
On the surface, the use of peptides as potential treatments for disease appears 
appealing; however, there are also innate properties of these compounds that have slowed 
or precluded their widespread use.  The major issues facing the development of peptide 
drugs are their low metabolic stabilities, which in turn results in poor bioavailability.  
Because of the large number of peptidases, serum half-lives for unmodified peptide-based 
drugs are relatively short, typically ranging from minutes to a few hours (15).  Short half-
lives often prevent intact peptides from reaching their intended targets.  Numerous 
strategies have been employed towards increasing the metabolic stabilities of peptides.  
These include: N-terminal modifications (e.g., N-acylation), use of D-amino acids, 
conformational constraint (e.g., cyclization), side-chain/backbone modification, and 
others (15, 16).  By making the peptide more resistant to proteolytic degradation, the 
likelihood of the drug reaching its intended target is greatly increased.   
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As a result of rapid rates of proteolytic degradation, peptide drugs also possess 
poor bioavailability following systemic administration.  Bioavailability is defined as “the 
rate and extent to which the active ingredient or moiety is absorbed from a drug product 
and becomes available at the site of action” (17).  In the case of peptide drugs targeting 
the CNS, the major obstacle to CNS delivery of peptides to their targets is the blood-brain 
barrier (BBB).  The BBB can best be described as a highly selective barrier between the 
CNS and the rest of the body.  The BBB is comprised of three tightly packed cell types at 
the capillary level.  Furthermore, tight junctions between endothelial cells prevent 
paracellular transport.  The BBB prevents passage of nearly all molecules except those 
nutrients that are small and lipophilic.  Receptors on the surface of the BBB facilitate the 
controlled passage of larger macromolecules such as glucose and some amino acids from 
the blood into the brain, but all other macromolecules are excluded.  A large number of 
efflux pumps on the surface of the BBB expel exogenous substances into the blood 
stream (17).  This highly selective barrier serves to protect the brain from exogenous 
substances, such as toxins, that may otherwise damage brain tissues (18). Much in the 
same way that peptides have been modified for increased metabolic stability, numerous 
efforts have been made to circumvent the BBB to gain therapeutic access to the brain.  
Some of these methods have included: lipidization, increased metabolic stability through 
structural modifications, glycosylation, use of nutrient transporters, prodrug strategies, 
vector-based delivery, cationization, and conjugation to polymer systems (16).  Many of 
these strategies take advantage of the inherent properties of the BBB to facilitate 




Table 1.1 Description of strategies commonly used to increase metabolic stability and 
improve bioavailability of peptide-based drugs (15, 16). 
 
 


































1.2 Initial Work 
 
1.2.1 The Cationization-Lipidization Strategy 
  It is the overall hypothesis of this work that analogs of endogenous 
neuropeptides can be engineered to increase metabolic stability and improve 
bioavailability upon systemic administration.  Our work has focused on the lipidization 
and cationization of the bioactive fragments of galanin (GAL), neuropeptide Y (NPY), 
neurotensin (NT), neuropeptide W (NPW), somatostatin (SOM), and erythropoietin 
mimetic peptides (EPM).  As mentioned previously, the strategies of cationization and 
lipidization have been employed separately towards overcoming the barriers facing 
peptide delivery into the CNS.  However, we observed that the combination of these 
strategies resulted in peptide analogs with improved serum half-lives, increased 
partitioning coefficients (logD), and were active in the 6 Hz mouse model of 
pharmacoresistant epilepsy (Figure 1.1).   
Attachment of fatty acid motifs increased the overall lipophilic character of the 
modified peptide.  Witt et al suggested that increased lipophilicity may facilitate passive 
diffusion of drugs across the BBB (16) (Figure 1.2).  They reported that lipophilicity, 
reflected by larger logD values, could be increased by altering the ratio between polar 
and nonpolar groups within a molecule (16, 19).  Furthermore, it has been reported that 
long chain fatty acids, such as palmitate, bind to serum albumin which may contribute to 
increased serum half-lives (20).  This information may aid in explaining our results where 






Figure 1.1 Overview of the lipidization-cationization strategy.  Using the minimal 
number of amino acid residues required for biological activity, lipoamino acid and poly-
lysine motifs were conjugated either centrally, or at the N- or C-terminus.  These 
strategies were then combined to afford peptide analogs with increased lipophilicity 
(logD), improved metabolic stability, and that were active in an animal model of 






Figure 1.2 Effects of differing logD values on CNS bioavailability.  The optimal range 
for compounds targeted to the brain spans logD values between 1 and 3.  Lower values 
result in compounds with lower permeability, while values above this range result in 
compounds with poor solubility and high metabolic liability.  Figure adapted from (17). 
11 
resulted in analogs with substantially increased logD and improved half-life (t1/2) values 
in an in vitro serum stability assay (21-25).   
Cationization of peptides has also been employed towards creating metabolically-
stable, BBB-permeable peptide analogs of peptide-based drugs.  It has been suggested 
that increased cationic character may assist in the delivery of peptides across biological 
membranes such as the BBB via absorptive-mediated endocytosis (16).  Increased 
metabolic stability may well result from increased binding of the peptides to serum 
albumin (26). It is still unclear where cationic peptides bind to albumin; but, Svenson and 
coworkers reported that cationic peptides ranging from three (cationic antibacterial 
peptide) to nine (vasopressin) amino acids bound to both human and bovine serum 
albumin with similar low micromolar affinities (26).  Applied independently, the 
strategies of cationization and lipidization have been shown to improve both metabolic 
stability and lipophilicity of peptide-based compounds.  However, this thesis will set out 
to illustrate that the combination of these two approaches resulted in analogs of 
endogenous neuropeptides with improved lipophilicity and increased metabolic stability 
that were also found to exhibit potent antiepileptic activity in the 6 Hz model of epilepsy 
following intraperitoneal (ip) administration.               
 
1.3 Research Objectives 
 
Nearly 30% of individuals that suffer from seizures are resistant to available 
treatments for epilepsy.  Furthermore, a rapidly increasing number of individuals suffer 
from chronic neuropathic pain.  As such, the need for alternative treatments for these 
neurological disorders goes unmet.  The primary goal of our research is to develop first-
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in-class therapeutics for the treatment of pain and epilepsy.  Therefore, we hypothesized 
that metabolically-stable, systemically-bioavailable analogs of endogenous neuropeptides 
could be generated using the combination of lipidization and cationization motifs.  
Testing of the overall hypothesis of this work was accomplished in the following four 
specific aims: 
 
1.3.1 Specific Aim I   
This aim tested the hypothesis that modification of the biologically-active 
fragment could improve upon the physicochemical and pharmacological properties of the 
known anticonvulsant neuropeptide galanin.  Analogs containing lipidization and 
cationization motifs were designed and synthesized.  Following synthesis structural, 
physicochemical, and pharmacological characterization of the analogs was conducted to 
determine which modifications lead to improved metabolic stability, BBB-permeability 
and anticonvulsant activities. 
 
1.3.2 Specific Aim II   
This aim focused on the extension of the lipidization-cationization strategy to 
other neuropeptides.  The hypothesis of this aim was that the lipidization-cationization 
strategy could be applied towards creation of metabolically-stable, BBB-permeable 
analogs of neurotensin and neuropeptide Y.  Similar to the galanin analogs described in 




1.3.3 Specific Aim III   
This aim tested the hypothesis that the lipidization-cationization strategy could be 
applied for the repositioning of analgesic peptides for use as anticonvulsants due to the 
common origins of the two neurological disorders.  Studies in support of this aim focused 
on the application of lipidization and cationization motifs to the analgesic peptide 
neuropeptide W.  Since neuropeptide W has been previously shown to modulate neuronal 
hyperexcitability, the underlying cause of both neuropathic pain and epilepsy, we 
explored the hypothesis that this endogenous neuropeptide could be repositioned for the 
treatment of seizure.  Analogs were designed, synthesized, and characterized with the aim 
of creating metabolically-stable, orally-bioavailable NPW analogs. 
 
1.3.4 Specific Aim IV  
Specific Aim IV tested the hypothesis that lipidization and cationization motifs 
could be coupled to peptides with single disulfide bridges towards creation of BBB-
permeable cyclic peptides.  As proof-of-concept that single disulfide bridge-containing 
peptides could be modified with lipidization-cationization motifs, analogs of somatostatin 
and erythropoietin were constructed.  Numerous pharmacologically-active peptides 
contain disulfide bridges necessary for their biological activities.  Construction of BBB-
permeable cyclic peptides may provide a framework for the design and synthesis of other 
pharmacologically-active peptidic compounds such as conotoxins, non-ribosomal (NRP) 
and ribosomal peptide (RP) natural products, and others. 
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GENERATING METABOLICALLY-STABLE, SYSTEMICALLY 
 





 Galanin is a multifaceted, endogenous neuropeptide that has been shown to 
modulate anticonvulsant behavior.  However, its use as an antiepileptic drug has been 
hindered by a lack of serum stability as well as poor CNS bioavailability.  We have 
sought to improve upon the physicochemical and pharmacological properties of this 
peptide through a combination strategy of cationization and lipidization.  As such, we 
identified a modified galanin analog (Gal-B2) which possessed improved metabolic 
stability, increased n-octanol/water partitioning (logD), and exhibited potent 
anticonvulsant activity in the 6 Hz mouse model of pharmacoresistant epilepsy.  My 
contribution to these efforts, described in the following chapter, illustrated how 
modifications of the Gal (1-16) active fragment influenced physicochemical properties 
such as serum stability and logD values.  This was accomplished through the use of two 
in vitro assays that monitored peptide stability and relative lipophilicity.  Furthermore, I 
examined the correlation between increases in these two properties and improved 
pharmacological activity in a mouse model of epilepsy.  
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2.2 Introduction 
2.2.1 Galanin and Gal-receptors as Targets for Pain and Epilepsy 
 Human galanin is an endogenous neuropeptide consisting of 30 amino acid 
residues (sequence: GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS-COOH).  Galanin 
was first isolated from porcine intestinal tissues in 1983 by Tatemoto and co-workers (1).  
It was initially implicated to play a role in the contraction of smooth muscle tissues, with 
the additional capability of modulating hyperglycemia (1).  Further research revealed that 
galanin is extremely diverse in its biological actions having been shown to be involved in 
the regulation of feeding behaviors, neuronal hyperexcitability, pain pathways, and 
anxiety (2). 
It has been shown that the N-terminal fragment of the peptide, Gal (1-16), binds 
with comparable low nanomolar affinity to that of the full-length peptide (3, 4).  
Moreover, Crawley and others have reported that central administration of the Gal (1-16) 
fragment was sufficient to elicit similar agonist activity to that exhibited by the full-
length peptide (4,5).  Unlike the N-terminal fragment, the C-terminal portion of galanin, 
Gal (17-29), exhibits no such behavior suggesting that the biological activity of galanin is 
contained within the sequence of the first sixteen amino acid residues (3, 6).  Alanine-
positional scanning experiments later identified residues within the bioactive fragment 
responsible for the effective binding and agonistic activities of Gal (1-16) as Trp2, Asn5, 
and Tyr9, in addition to the N-terminal amine.  Mutations to these residues resulted in 
drastic differences in ligand binding affinity for galanin receptors (3).   Using available 
structure-activity data, researchers have set out to develop both small molecule and 
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peptide-derived GalR agonists with the aim of developing compounds capable of treating 
various neurological disorders. 
 Galanin exerts its biological actions by activating one of three G protein coupled 
receptor targets (GalR1, GalR2, or GalR3) (4, 7).  GalR3 has been identified and cloned; 
however, the precise function of this receptor unclear at the present time, it is not 
expected to play a role in epilepsy. Studies have shown that the receptor subtypes are 
located centrally (brain and spinal chord), peripherally (peripheral neurons such as dorsal 
root ganglion), and in the gut tissues.  As mentioned previously, galanin plays an 
important role in the neuroendocrine system activation of the GalR-subtypes and signals 
the release of certain hormones for the modulation of feeding behaviors.  However, more 
relevant to our work, is the ability of this peptide to control neuronal excitability from 
which neurological disorders such as neuropathic pain and epilepsy originate (2, 8).  Ito 
and coworkers proposed that galanin inhibits neuronal excitability via hyperpolarization 
of the cell membrane by increasing K+ conductance and decreasing Ca2+ conductance (9).  
Previous studies have shown that GalR1, GalR2, as well as galanin itself, can be found at 
elevated levels in the hippocampus of the brain (4).  The presence of galanin and its 
respective receptors in this region are of significance because damage to the hippocampus 
has been implicated in epileptogenesis (10).  In support of this idea, GalR1 knock-out 
studies in mice showed an increase in frequency and severity of pilocarpine-induced 
seizures (11).  Furthermore, Mazarati and others have previously shown that direct 
intracerebroventricular (i.c.v.) injection of galanin (1-29) into the hippocampus inhibited 
seizure activity in pertussis-toxin (PTX) treated rats (11).                   
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2.2.2 Current Approaches to Targeting Gal-receptors: Small  
Molecule Versus Peptide-based Galanin Analogs 
 Two small molecule GalR agonists of particular interest are galmic and galnon.  
These compounds exhibited increased resistance to serum degradation and were shown 
active in animal models of epilepsy (12, 13).  Though small molecule GalR agonists, 
such as galmic and galnon, have shown promise as antiepileptic drugs, receptor binding 
affinities were significantly lower than those exhibited by peptide-based galanin agonists 
(μM versus nM) (14). Furthermore, galnon was shown to act on numerous GPCRs aside 
from Gal-receptors (i.e., off target effects) (15).  Numerous peptide-derived GalR 
agonists have also been previously reported in the literature (16).  However, these 
analogs lacked either the metabolic-stability or BBB-permeability necessary for further 
development as systemically-bioavailable treatments for neurological disorders (17).  As 
such, there is still an unmet need for peptide-based compounds that are systemically-
bioavailable. 
 
2.2.3 The Lipidization-Cationization Strategy 
 In order to create systemically-active peptide-based agonists of GalR1 or GalR2, 
metabolic stability and BBB-permeability must be improved.  As mentioned in the 
previous chapter, numerous strategies have been employed to overcome the inherent 
shortcomings of peptide-based drugs.  However, current approaches have met with 
limited success.  We showed that the combination of lipidization and cationization 
applied to the bioactive fragments of endogenous neuropeptides resulted in peptide 
analogs possessing improved metabolic stabilities, increased logD values that also 
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possessed potent anticonvulsant properties in the 6 Hz pharmacoresistant model of 
epilepsy.  This strategy has been studied extensively through our development of galanin 
analogs possessing the lipidization-cationization motifs (17-20). The following section 
will highlight our findings with respect to this approach.  Specifically, this chapter will 
place special emphasis on my individual role in studying how these modifications 
influence physicochemical properties such as serum stability and n-octanol/water 
partitioning coefficients (logD). 
 
2.3 General Methods and Materials 
 A complete description of methods and materials relevant to this chapter can be 
found in the attached manuscripts (17-20). 
 
2.4 Results and Discussion 
Results presented in this section are a compilation of data, published and 
unpublished, from the attached manuscripts (17-20).  Special emphasis will be placed on 
the relationships between galanin analog structure and physicochemical attributes such as 
metabolic stability and partitioning coefficient (logD).  To date, over 120 analogs of 
galanin have been designed and synthesized.  A number of these compounds have been 
further examined to determine which structural properties translate into metabolically-
stable, systemically-bioavailable anticonvulsant galanin analogs. 
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2.4.1 Relationship Between Structure and Metabolic Stability  
of Galanin Analogs 
It was observed from the in vitro serum stability data that the modifications made 
to the galanin active fragment (i.e., lipidization-cationization motifs) significantly 
improved the t1/2-values for the analogs.   This becomes apparent through comparison of 
the t1/2-values for each of the modified analogs to that of Gal (1-16) (Table 2.1). 
By plotting the t1/2-values, several important observations could be made with 
regard to structure-stability relationships (Figure 2.1).  First, addition of either the 
lipidization or cationization motifs, individually, had an immediate effect on serum half-
lives.  Introduction of a oligo-lysine motif in the Gal-K(4) analog increased the half-life 
to approximately 4.7 h.  This is consistent with previous work on endomorphin I and II 
which showed that increased cationic character resulted in increased resistance to 
proteolytic degradation (21, 22).  It was hypothesized that this increase may arise from 
limited protease accessibility to sensitive N- or C-terminal regions (21).  Furthermore, 
conjugation of a lipoamino acid motif appears to be the major contributor for improved 
metabolic stability.  Coupling of Nε-palmitoyl-L-lysine to the C-terminus of Gal (1-15) in 
the Gal-LAA analog exhibited serum stability of over 15 h.   
Second, examination of the fatty acid motif revealed direct correlation between 
the length of the fatty acid and t1/2 values (19).  Through synthesis of a series of analogs 
in which the length of the fatty acid varied from C8 to C18, it was shown that chain lengths 
longer than C10 and shorter than C18 yielded t1/2 values greater than 8 h.  It was 
hypothesized that the observed increase in serum stability may result from i) limitation of 
proteases that would typically degrade the unmodified peptide and/or ii) through 
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Table 2.1 Summary of in vitro serum stability data for galanin analogs. 
 
 Galanin Analog Sequence t1/2 (h)
1 Gal (1-16) GWTLNSAGYLLGPHAV 0.13 
2 Gal-B2-C8 (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K 3.1 
3 Gal-K(4) (Sar)WTLNSAGYLLGPKKKK 4.7 
4 Gal-B8 (Sar)WTLNSAGYLLGPRR(Kp)R 4.8 
5 Gal-B2-C10 (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K 5.5 
6 Gal-B11 (Sar)WTLNSAGYLLGKK(Kp)K 5.6 
7 Gal-B2-C18 (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K 7.2 
8 Gal-B3 (Sar)WTLNSAGYLLGPK(Kp)KK 8.6 
9 Gal-B2-C14 (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K 8.6 
10 Gal-B10 (Sar)WTLNSAGYLLKKKK(Kp)K 8.7 
11 [N-Me,des-Sar] Gal-B2 (N-Methyl-Trp)TLNSAGYLLGPKK(Kp)K  9.0 
12 Gal-B2 (Sar)WTLNSAGYLLGPKK(Kp)K 9.4 
13 Gal-B5 WTLNSAGYLLGPKK(Kp)K 10 
14 Gal-B1 (Sar)WTLNSAGYLLGPKKK(Kp) 10.3 
15 Gal-B2-C12 (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K 11.5 
16 Gal-B12 (Sar)WTLNSAGYLLKK(Kp)K 12.0 
17 Gal-B2-MPEG4 (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K 15.0 
18 Gal-B6 GWTLNSAGYLLGPKK(Kp)K > 15 
19 Gal-LAA (Sar)WTLNSAGYLLGPHA(Kp) > 15 
20 Gal-B4 (Sar)WTLNSAGYLLGP(Kp)KKK > 15 
21 Gal-B9 (Sar)WTLNSAGYLLGP(D-K)(D-K)(Kp)(D-K) > 15 
 
Table summarizes galanin analogs, amino acid sequences and calculated serum half-
lives (t1/2) for compounds studied in an in vitro serum stability assay.  Analogs were 
incubated in the presence of 25% rat blood serum, 0.1 M Tris-HCl, pH 7.4 and nH2O at 
37 °C for 8 h.  At discrete time points (0, 0.5, 1, 2, 4, and 8 h) reactions were quenched, 
precipitated, and supernatants analyzed by analytical HPLC.  Degradation was 
determined as the disappearance of the native peptide with respect to time.  The t1/2-
values were obtained from the average of at least three independent time-course 
experiments. Colors represent relative half-lives for each of the analogs (Black: 0-4 h, 








Figure 2.1 Serum stability of modified galanin analogs.  Each point represents the 
average of at least three independent time course experiments.  Analogs were divided into 
four groups based on calculated t1/2 values: Black (0-4 h), Purple (4-8 h), Blue (8-12 h), 




increased stability by binding of the lipidized peptide to fatty acid binding sites on serum 
albumin (19).  Interestingly, it was also observed that above C14, t1/2-values began to 
decrease with the extension of the fatty acid motif with each additional ethylene group 
(Gal-B2-C16 and Gal-B2-C18); suggesting an optimal fatty acid chain length with respect 
to serum stability.  These results were consistent to those of van de Waterbeemd et al 
who suggested that increased lipophilicity, beyond a certain threshold, may result in 
increased metabolic liability (23).   
Third, it was shown that maximal metabolic stability could be attained through i) 
“shifting” of the lipoamino acid towards the N-terminus (Gal-LAA and Gal-B4), ii) 
conjugation of polymers such as monodispersed PEG4 (Gal-B2-MPEG4), and iii) 
incorporation of peptidase-resistant D-amino acids (Gal-B9).  It was observed that direct 
conjugation of the lipoamino acid to the C-terminus of the galanin active fragment 
resulted in t1/2-values greater than 15 h. It is thought that the fatty acid tail may act to 
prevent endopeptidase access to the peptide backbone.  However, in these analogs, we 
also observed a loss in pharmacological activity, resulting from steric interference of the 
bulky modification with respect to receptor binding (18).  Polymer-mediated transport 
using polyethylene glycols has been employed for delivery of numerous biomolecules 
(24).  In the context of the lipidization-cationization strategy, the MPEG4 modification 
was shown to have a dramatic effect on the serum stability of the galanin analog Gal-B2-
MPEG4.  Similar to the internally truncated peptides, this analog exhibited improved 
stability, but was significantly less active in the 6 Hz model of epilepsy.  Finally, 
modification of the cationization motif, by incorporation of D-Lys, yielded the largest 
increase in t1/2 (Gal-B9).  As many proteases are not active on D-amino acids, this strategy 
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remains one of the most promising options for increasing peptide stability.  However, as 
suggested by Youngblood, the development of peptide libraries containing D-amino acids 
may be limited by the relatively high cost of these amino acid residues (25).      
 
2.4.2  Relationship Between Structure and Partitioning Coefficient  
(logD) of Galanin Analogs 
 The next physicochemical property explored was that of lipophilicity.  
Octanol/water partitioning (logD) is currently one of the most employed methods for 
description of compound lipophilicity.  The values obtained from these experiments are 
often used to describe the potential for a compound to penetrate biological membranes 
such as the BBB.  LogD values were assessed either by the shake-flask method or by 
determination of the capacity factor (k’) using HPLC retention times (17-19).  A linear 
relationship exists between experimental logD values and HPLC retention times (23) 
(Figure 2.2).  A summary of the HPLC retention times and logD values calculated by 
either of these two methods is summarized in Table 2.2. 
Plotting the data obtained for each of the analogs provided important information 
regarding the effects of the lipidization-cationization strategy on logD values (Figure 
2.3). The Gal (1-16) fragment by itself was modestly hydrophobic without further 
modification (logD = 0.7).  When an oligo-Lys motif was added to the C-terminus (Gal-








Figure 2.2 Correlation between HPLC retention times and logD.  Each point represents 
the average of three logD experiments for the analogs listed in Table 2.2.  LogD values 
of Gal (1-16), Gal-K(4), Gal-B2, and Gal-LAA were determined by the shake-flask 
method.  These values were plotted against retention time to create a standard curve by 













Time (min) LogD 
1 Gal-K(4) (Sar)WTLNSAGYLLGPKKKK 15.13 ± 0.42 0.40 ± 0.05 
2 Gal-B2-MPEG4 (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K 17.57 ± 0.01 0.57 ± 0.00 
3 Gal (1-16) GWTLNSAGYLLGPHAV 19.32 ± 0.37 0.69 ± 0.02 
4 Gal-B2-C8 (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K 20.13 ± 0.05 0.78 ± 0.01 
5 Gal-B2-C10 (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K 21.49 ± 0.05 0.90 ± 0.01 
6 Gal-B6 GWTLNSAGYLLGPKK(Kp)K 22.53 ± 0.42 0.96 ± 0.24 
7 Gal-B2-C12 (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K 22.51 ± 0.03 1.06 ± 0.01 
8 Gal-B10 (Sar)WTLNSAGYLLKKKK(Kp)K 24.00 ± 0.13 1.08 ± 0.02 
9 Gal-B2-C14 (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K 23.76 ± 0.03 1.18 ± 0.01 
10 Gal-B9 (Sar)WTLNSAGYLLGP(D-K)(D-K)(Kp)(D-K) 25.44 ± 0.12 1.21 ± 0.02 
11 Gal-B5 WTLNSAGYLLGPKK(Kp)K 25.62 ± 0.10 1.22 ± 0.02 
12 Gal-B11 (Sar)WTLNSAGYLLGKK(Kp)K 25.67 ± 0.14 1.23 ± 0.02 
13 Gal-B2 (Sar)WTLNSAGYLLGPKK(Kp)K 25.84 ± 0.10 1.24 ± 0.02 
14 Gal-B4 (Sar)WTLNSAGYLLGP(Kp)KKK 25.88 ± 0.14 1.24 ± 0.02 
15 Gal-B12 (Sar)WTLNSAGYLLKK(Kp)K 25.82 ± 0.10 1.24 ± 0.02 
16 Gal-B3 (Sar)WTLNSAGYLLGPK(Kp)KK 25.96 ± 0.29 1.25 ± 0.03 
17 Gal-B1 (Sar)WTLNSAGYLLGPKKK(Kp) 25.99 ± 0.16 1.25 ± 0.03 
18 Gal-B8 (Sar)WTLNSAGYLLGPRR(Kp)R 26.26 ± 0.09 1.28 ± 0.02 
19 [N-Me,des-Sar] Gal-B2 (N-Methyl-Trp)TLNSAGYLLGPKK(Kp)K 31.5 ± 0.01 1.29 ± 0.01 
20 Gal-B2-C18 (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K 26.73 ± 0.18 1.35 ± 0.02 
21 Gal-LAA (Sar)WTLNSAGYLLGPHA(Kp) 28.31 ± 0.04 1.45 ± 0.02 
 
Table summarizes galanin analogs, amino acid sequences HPLC retention times, and 
calculated logD values.  Values were calculated using either the shake-flask method or 
by HPLC capacity factor (k').  Colors represent the range of logD values for each of the 
analogs (Black: 0-1.0, Purple: 1.0-1.25, Blue: 1.25-1.5).  Data were collected as the 
average of three independent experiments.  All samples were analyzed by analytical 
HPLC over a linear gradient ranging from 20-100% solvent B (90% acetonitrile, 0.1% 








Figure 2.3 Effects of the lipidization-cationization strategy on logD values.  Data 
represent the average logD values obtained from three independent experiments.  
Individually, lipidization and cationization had dramatic effects on logD.  Increased 
cationization resulted in analogs with logD values lower than that of the galanin active 
fragments (logD Gal-(K)4 = 0.4); whereas, lipidization of the active fragment 
dramatically increased logD (logD Gal-LAA = 1.45).  The majority of analogs 
containing lipidization-cationization motifs had logD values of about 1.24.   Analogs 
were divided into three groups based on logD values: Black: 0-1.0, Purple: 1.0-1.25, 
Blue: 1.25-1.5.   
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reflected by a lower logD of 0.4.  This is due to the increased number of basic residues, 
which exhibit a positive charge at physiological pH.  Likewise, conjugation of the Lys-
PEG4 decreased the logD value, presumably by the same means.  Similar to serum 
stability data, there was good correlation between the length of the fatty acid motif and 
increased logD values where C8 < C10 << C18 (19).  As mentioned in the introductory 
chapter, logD values in ranging from 1-3 are ideal for good CNS penetration; the C8 and 
C10 fatty acids fall just short of this range, but did exhibit some anticonvulsant activity in 
the 6 Hz mouse model of epilepsy (19, 23). When the lipoamino acid was coupled 
directly to the bioactive fragment (Gal-LAA), a dramatic shift in retention time was 
observed (logD =1.45).  This would suggest that the presence of the lipoamino acid is the 
key determinant for increased logD.  Combination of the lipidization and cationization 
strategies resulted in a number of galanin analogs with logD values at or near 1.24.  The 
largest logD values were observed in the Gal-B2-C18 and Gal-LAA analogs, suggesting 
that increased chain length or a decrease in charge results in increased lipophilicity.   
In addition to increased serum half-lives conferred by the lipidization-
cationization motifs, it was also concluded that these modifications influenced the 
lipophilicity of galanin analogs.  Through modification of the galanin active fragment, we 
were able to generate compounds with increased logD (0.69 for Gal (1-16) compared to ≥ 
1.24 for modified analogs).  Most peptide-based drugs do not cross the BBB because of i) 
overall hydrophilic character of the peptide and ii) the absence of specific peptide 
transport systems on the BBB membrane. (23, 24).  By coupling of lipophilic motifs, 
such as fatty acids, the balance is shifted towards making the compounds more 
hydrophobic and therefore increases the rates of passive diffusion across the BBB (24).  
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It is the conclusion of this study, that attachment of the fatty acid to the ε-amine of one of 
the Lys-residues within the lipidization-cationization motif sufficiently improved logD 
values for increased penetration into the BBB.  Neither the position of the LAA, central 
truncation of the bioactive fragment, nor the composition of the cationization motifs had 
a significant effect on logD; the major determinant of logD is likely the length of the fatty 
acid.   
 
2.5 Publications 
The following subsections will include publications relevant to the galanin 
project.  All manuscripts lend support to the main goal of this project which is to develop 
metabolically-stable, systemically-bioavailable galanin analogs that possess potent 
anticonvulsant activity.  Furthermore, results from the in vitro serum stability and logD 
assays are further described.  Section 2.4.1 focuses on the application of lipidization-
cationization motifs to GAL (1-16).  Design, synthesis, and both physicochemical and 
pharmacological characterization are described.  LogD and serum stability data from a 
number of galanin analogs will be described in this chapter.  Section 2.4.2 describes the 
synthesis and characterization of Gal-B2 analogs containing alternative lipidization 
motifs conjugated to the ε-amine of Lys-16.  The pharmacological consequences of these 
modifications in addition to their effect on serum stability and logD values are illustrated 
in this subsection.  Section 2.4.3 is an in-depth look at the pharmacological properties of 
the Gal-B2 (NAX-5055) analog.  Finally, Section 2.4.4 will describe efforts in 
developing subtype-selective Gal-B2 based analogs through a strategy of “atom shaving” 
of the N-terminus.  Using the Gal-B2 analog, we showed that removal of atoms from the 
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N-terminus yielded metabolically stable, systemically bioavailable galanin analogs that 
exhibited preference for the GalR2 subtype. 
33 
2.5.1 Design, Synthesis, and Characterization of High-Affinity,  
Systemically-Active Galanin Analogues with Potent  
Anticonvulsant Activities 
 
Manuscript Reproduced with Permission From:  
Bulaj, G., Green, B. R., Lee, H.-K., Robertson, C. R., White, K., Zhang, L., Sochanska, 
M., Flynn, S. P., Scholl, E. A., Pruess, T. H., Smith, M. D., and White, H. S. (2008) 
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 The compounds described in this section constitute our efforts to elucidate how 
lipidization and cationization motifs influence the physicochemical and pharmacological 
properties of galanin analogs such as metabolic stability and logD.  Though modest 
improvements to logD and serum stability were observed by implementation of either the 
lipidization or cationization motifs, individually, it was the combination of these two 
strategies that yielded the most promising results.  Furthermore, only by combining the 
two strategies were the potent anticonvulsant effects observed. Our results showed that 
the key determinant for improved physicochemical properties was the presence, and 
chemical structure, of the attached fatty acid.  Follow-up experiments have focused on 
further modification of Gal-B2 through incorporation of alternative lipidization motifs 
(i.e. unsaturated fatty acids), conformational constraint (via lactamization), and others.  
Aside from galanin a number of endogenous neuropeptides have also been implicated as 
having important neuromodulatory roles in pain pathways and in seizure control.  The 
following chapters will explore the potential for application of the lipidization-
cationization strategy described here for the development of systemically-active analogs 
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ANALGESIC NEUROPEPTIDE W SUPPRRESSES SIEZURES IN THE  
 
BRAIN REVEALED BY RATIONAL REPOSITIONING  
 




Various neuropeptides play an important neuromodulatory role in controlling 
neuronal hyperexcitability that leads to pain or seizures. Based on overlapping inhibitory 
mechanisms, anticonvulsant compounds exhibit concurrent analgesic and antiepileptic 
activities. The recently deorphanized neuropeptide W (NPW), targets the G-protein 
coupled receptors NPBW1 (GPR7) and NPBW2 (GPR8). This peptide was previously 
shown to possess analgesic properties, in addition to controlling feeding and energy 
metabolism coupled to brain levels of leptin. Given the similar mechanistic origins of 
pain and seizure, we tested the hypothesis that the analgesic activity of NPW may lead to 
the discovery the antiepileptic activity of this peptide. Indeed, intracerebroventricular 
(i.c.v.) administration of NPW potently reduced seizures in the 6 Hz psychomotor seizure 
model in mice. Subsequently, we rationally designed, synthesized, and characterized 
metabolically-stable NPW analogs aimed to penetrate the blood-brain barrier (BBB). The 
NPW analogs containing backbone spacers, a lipoamino acid and oligo-Lys motifs 
demonstrated anticonvulsant activity following systemic (intraperitoneal) administration. 
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Our results provided proof of concept that the combination of the repositioning strategy 
and engineering BBB-penetrating neuropeptide analogs could provide new drug leads for 
the treatment of pain and/or epilepsy.  Furthermore, our lead analog, NPW-B1, has a 
potential for studying the anorexic effects of NPW. We suggest that rational repositioning 
of biologics is an attractive tool for discovering new functions of already well 
characterized peptides and proteins. 
 
4.2 Introduction 
Neuropathic pain and epileptic seizures both result from an imbalance between 
excitation and inhibition of neuronal firing.   This imbalance is typically caused by 
agonism of excitatory neurotransmission or by antagonism of inhibitory 
neurotransmission. The recent use of antiepileptic compounds for the treatment of pain 
(repositioning) is largely due to the compounds’ ability to inhibit excessive firing in 
neurons through voltage and ligand-gated ion channel activities (1).  It has been well 
documented that several anticonvulsant neuropeptides possess concurrent antiepileptic 
and analgesic activities (Table 4.1). For example, galanin (Gal), neuropeptide Y (NPY), 
and somatostatin (SOM) are well know for their abilities to control seizures in the brain 
(2-4) in addition to exerting analgesic activities (5-7). Past studies of neurotensin (NT) 
and enkephalin (Enk) widely focused on their analgesic activities; however these peptides 
were recently shown to also act as potent anticonvulsants (8-10). The mutual relationship 
between analgesic and anticonvulsant properties of neuropeptides suggests that 
repositioning may be an attractive approach to discover their new functions.  
Recently, two highly homologous endogenous neuropeptides, neuropeptide W 





Table 4.1 Examples of neuropeptides that possess both analgesic and antiepileptic 
activities in animal models of pain and epilepsy. 
Neuropeptide Analgesic Activity Antiseizure Activity 
Galanin Model: formalin inflammatory pain 
assay (5) 
Model: self-sustaining status 
epilepticus (31)       
                                                     
NPY Model: hindpaw withdraw latency 
and Randall Selitto assay (6)               
Model: electrical hippocampal 
stimulation and kainate seizure 
(3) 
Somatostatin Model: foot-pressure assay (7) Model: quinolinic/kainic acid-
induced seizure (4)                        
Neurotensin Model: hot plate and writhing 
assays (39)   
Model: 6 Hz partial 
psychomotor seizure (8)               
Enkephalin Model: radiant-heat tail flick assay 
(40) 
Model: 6 Hz partial 
psychomotor seizure (9)               
NPW/NPB Model: partial sciatic nerve ligation 
assay (14) 
Model: 6 Hz partial 
psychomotor seizure. This work 
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(GPR7) and/or NPBW2 (GPR8) receptors (Figure 4.1) (11).  NPW binds to both 
NPBW1 and NPBW2 with low nanomolar affinity (Ki = 0.14 and 29 nM, respectively).  
Early studies showed that NPW played an important role in modulating feeding behaviors 
(11, 12).  Subsequent studies revealed that intrathecal (i.t.) administration of this peptide 
suppressed inflammatory pain in the mouse formalin test.   
NPW was also shown to be anti-allodynic in partial sciatic nerve ligation model 
(13-15).  Of particular interest, Zaratin and coworkers reported increased expression of 
NPBW1 receptor subtypes in myelin-forming Schwann cells in animal models of acute 
inflammatory and trauma-induced neuropathic pain suggesting a central role for this 
peptide as an analgesic (16).  Price et al showed that direct injection of NPW-23 into the 
hypothalamus influenced the excitability of specific groups of neurons in rats (17, 18).  In 
short, NPW has been shown to be a multifunctional endogenous ligand for NPBW1 and 
NPBW2 where it plays an important role in modulating pain pathways and feeding 
behaviors (19). In this work we tested the hypothesis that, based on its analgesic 
properties, NPW may also suppress seizures when delivered into the brain. The 
anticonvulsant properties of NPW were confirmed following i.c.v. injections, as well as 
by engineering metabolically-stable and BBB-penetrant NPW analogs using a design 
strategy previously applied to GAL, NPY and NT (10, 20, 21).   
 
4.3 Materials and Methods 
 
4.3.1 Intracerebroventricular (i.c.v.) Administration of NPW   
The 6 Hz partial psychomotor seizure test was performed to assess the 








Figure 4.1 Comparison of the primary amino acid structures of neuropeptide W and 
neuropeptide B.  Boxed regions denote areas of sequence homology between the two 
peptides.  These fragments have been previously found necessary for high affinity 
binding to the GPCR targets NPBW1 and NPBW2.  C-Terminally truncated NPW 
(NPW-23) was previously shown to exhibit similar binding properties and effective 






human NPW-23 (purchased from American Peptide Company, Inc.) were prepared in 
0.9% saline and were diluted to the required concentration prior to i.c.v. injections.  The 
time to peak anticonvulsant effect (TPE) was first determined at 0.25, 0.5, 1, 2, and 4 h 
following i.c.v. injection at a concentration of 1 nmol/5 μL (22, 23).  The TPE was 
calculated as the time at which 50% of animals were considered protected from seizure.  
For i.c.v. administrations, the test solution was administered in a volume of 5 µL, using a 
Hamilton syringe (size number 701), directly through the skull to a depth of 3 mm into a 
lateral ventricle of the brain.  A current of 32 mA was administered via corneal electrodes 
for 3 s in order to elicit psychomotor seizure.  Animals not displaying seizures were 
considered “protected” (22, 23).  Finally, an ED50, confidence interval, line slope, and 
standard error (S.E.M.) of the slope were calculated by Probit analysis.  Results were 
reported to two decimal places (24) 
 
4.3.2 Chemical Synthesis   
Synthesis of NPW analogs was carried out using a Symphony automated peptide 
synthesizer (Protein Technologies, Inc).  Syntheses were carried out at 100 μmol scale 
using Fmoc-Leu Amide-AM resin (subs. 0.71 meq/g).  Triple couplings of each amino 
acid (30, 30, and 40 min) were performed using 0.2 M PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate), 0.4 M DIPEA (N,N-
diisopropylethylamine), and 200 mM of each amino acid.  Protected amino acids, 
including Fmoc-Lys(palmitoyl) and Fmoc-5-aminovaleric acid were obtained 
commercially from Chem-Impex International.  Peptides were cleaved from resin by 
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treatment with reagent K (82.5% TFA, 5% water, 5% ethanedithiol, 2.5% thioanisole v/v, 
75 mg/mL phenol) followed by vacuum filtration to separate peptide from resin, and 
finally precipitated with chilled methyl-tert-butyl ether.  Crude peptides were then 
purified by preparative reversed-phase HPLC over a linear gradient of solvent B (90% 
acetonitrile in 0.1% TFA) ranging from 5 to 95% in 45 min. Solvent A was 0.1% TFA in 
water. Purities of separated fractions were assessed by analytical reversed-phase HPLC 
using a linear gradient ranging from 5 to 95% of solvent B in 30 min.  HPLC fractions 
with peptide purities greater than 95% were pooled and quantified by measuring UV 
absorbance at 279.8 nm.  Molecular masses of all analogs were confirmed by MALDI-
TOF MS. 
 
4.3.3 Partitioning Coefficient (logD)   
4.3.3.1 Shake-flask method. For selected analogs, logD values were calculated 
experimentally using the shake-flask method, as previously described (20, 25).  Briefly, 
water-saturated n-octanol was prepared by mixing equal volumes of n-octanol and water 
for 24 h at room temperature. Lyophilized peptides (0.1 mg) were then reconstituted in 1 
mL phosphate-buffered saline (PBS), followed by addition of an equal volume of water-
saturated n-octanol.  Samples were then allowed to mix on a rotary mixer for 24 h.  
Following mixing, samples were then allowed to settle for 15 min.  Aqueous phases were 
carefully removed and analyzed by analytical HPLC over a gradient of solvent B ranging 
from 5 to 95% in 30 min.  The amount of peptide in the aqueous phase was determined 
by HPLC using a standard curve constructed for each peptide.  LogD values for each 










loglog D                                           (4.1) 
4.3.3.2 HPLC capacity factor (k’) method.  For remaining NPW analogs, logD 
values were calculated by comparison to HPLC retention times with experimentally-
determined samples.  Briefly, 5 μg standards of each peptide were injected, in triplicate, 
onto a Vydac diphenyl HPLC column over a linear gradient ranging from 5-95% solvent 
B in 45 min.  The average retention time for each peptide standard was then used to 
calculate capacity factors (k’) using Equation 4.2 seen below. In this equation t0 is the 
solvent front and tr is the retention time of each peptide standard.  LogD values obtained 
experimentally from the shake-flask method were then plotted against their respective k’ 
values, yielding a linear plot.  This plot was then used to determine the logD values for 





ttk r −=                                                                        (4.2) 
4.3.4 Serum Stability Assay   
The stability of peptides in the presence of 25% rat blood serum was evaluated for 
each analog by incubation at 37 °C for 0 min, 30 min, 1 h, 2 h, 4 h, and 8 h.  Samples 
were prepared by adding 10 μg of a peptide, resuspended in nH2O, to pre-heated tubes 
containing 25% rat blood serum and 0.1 M Tris-HCl, pH 7.5.  At the appropriate time 
points, reactions were quenched by precipitation of serum proteins through addition of 
100 μL isopropanol / water / trichloroacetic acid (45%:40%:15% v/v/v).  Samples were 
then incubated at -20 °C for 20 min followed by centrifugation at 10,000 rpm for 3 min to 
remove serum proteins.  Supernatants were then removed and were analyzed by 
analytical HPLC equipped with a Waters YMC ODS-A 5μm 120 Å column using a 
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gradient ranging from 5% to 95% solvent B in 45 min including a 15 min pre-
equilibration step.  Metabolic stability was assessed by the determining a time-course of 
the disappearance of an intact peptide.  Half-lives (t1/2) for each peptide were determined 
from at least three independent time-course experiments using Equation 4.3 (where m is 
the slope of the line and b is the y-intercept): 
m
bht ])50[ln()(2/1
−=                                                          (4.3) 
 
4.3.5 Anticonvulsant Activity   
The anticonvulsant activity of the analogs was studied in the 6 Hz (32 mA) partial 
psychomotor model of pharmacoresistant epilepsy following a bolus intraperitoneal (i.p.) 
administration of a dose of 4 mg/kg to adult male CF-1 mice (n = 4).  For i.p. 
administrations, test substances were administered to mice in a volume of 0.01 mL/g of 
body weight.   At 30 min post administration, mice were challenged with a 6 Hz corneal 
stimulation (32 mA for 3 s delivered via corneal electrodes).  In adult, male CF-1 mice, 
the convulsive current required to evoke a partial seizure in 97% (CC97) of mice is 
22 mA.  The 32 mA current used in the present study represents 1.5 times the CC97 of 
adult male CF-1 mice will display a partial seizure Mice which did not exhibit classical 
limbic seizure behavior were classified as protected (27).  This model is useful for 
discriminating drugs such as levetiracetam, that lack sensitivity to traditional screening 
models like the maximal electroshock (MES) or the subcutaneous pentylenetetrazol 
(scPTZ) models, but maintain their anticonvulsant activity as the current is increased to 
32 mA (1.5 times CC97) and then 44 mA (2 times the CC97) (22, 28).  Typically, the 
seizure phenotype is characterized by a minimal clonic phase that is followed by 
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stereotyped, automatistic behaviors described originally as being similar to the aura of 
human patients with partial seizures.  Animals not displaying this behavior were 
considered protected.  In addition to the 6 Hz screening of all analogs at the 30 min time 
point, dose-response studies were carried out for hNPW-23 (i.c.v. administration only) 
and NPW-B1 (i.p. administration).  Briefly, peptide analogs were administered and at 
30 min, mice were challenged with a 32 mA corneal stimulation.  Based on the numbers 
of protected animals at each dosage, ED50 values were determined for each peptide using 
Probit software (24).                                                                                                                                            
 
4.3.6 Rotorod Testing   
The rotorod procedure was used to disclose minimal muscular or neurological 
impairment.  Briefly, the mouse was placed on a rod that rotated at a speed of 6 rpm, in 
order for the animal to maintain its equilibrium for extended periods of time.  The animal 
was considered motor impaired (toxic) if it fell off of the rotating rod three times during a 
one min observation period (29).  
 
4.3.7 Animal Care   
Adult male CF No. 1 albino mice (26-35 g), obtained from Charles River 
(Portage, Michigan), were utilized for behavioral testing in both the 6Hz test and the 
rotorod procedure. The animals were maintained on an adequate diet (Prolab RMH 3000) 
and allowed free access to food and water, except during the short time they were 
removed from their cage for testing.  The animals were housed, fed, and handled in a 




4.4.1 Intracerebroventricular (i.c.v.) Administration of hNPW-23   
To test the hypothesis that analgesic NPW can also suppress seizures, this peptide 
was evaluated in the 6 Hz (32 mA) psychomotor seizure test in mice.  Neuropeptide W-
23 was injected i.c.v. into adult, male CF-1 mice. Mice were tested at 0.01, 0.1, 1, 2, and 
4 nmol concentrations (per 5 μL injection volume), and were evaluated after 15 min post-
drug administration.  At these doses 2/8, 4/8, 5/8, 6/8, and 6/8 mice, respectively, were 
protected from the seizure activity.  At each concentration, 1/8 mice displayed rotorod 
toxicity.  The ED50 value was calculated as 0.24 nmol with a 95% confidence interval of 
0.003-1.2 nmol (b = 0.52 ± 0.22).   
Similarly, the effect of NPB-29 in the 6 Hz epilepsy model in adult, male CF-1 
mice was also evaluated.  The time of peak effect was determined to be 0.25 h following 
i.c.v. administration.  Mice were tested at 0.1, 1.0, 1.5, and 2 nmol concentrations (per 5 
μL i.c.v. injection volume).  At these doses, 1/8, 2/8, 4/8, and 6/8 mice were protected 
from seizure activity, respectively (Figure 4.2).  Furthermore, at these doses 0/8, 3/8, 
3/8, and 4/8 mice were found to display motor toxicity, respectively.  The ED50 was 
determined to be 1.5 nmol with a 95% confidence interval of 0.4-128 nmol (b=1.2 +/- 
0.56).  Notably, the ED50 value determined for NPB-29 (1.5 nmol/5ul) was 
approximately six fold higher than that which was determined for NPW-23 in the 6 Hz 
partial psychomotor seizure test at 32mA.  This is the first report on the antiepileptic 












Figure 4.2 Summary of anticonvulsant activities of hNPW-23 and NPB-29 following 
i.c.v. administration.  Peptides were injected i.c.v. into adult male CF-1 mice.  Mice 
were tested at 0.01, 0.1, 1.0, 2 and 4 nmol/5 μL for hNPW-23 and 0.1, 1.0, 1.5, and 2 
nmol/5 μL for NPB-29.  Data represent the number of animals which did not exhibit 
classical seizure-type behaviors at 0.25 h post drug administration. ED50 values were 
calculated at 0.24 nmol (95% CI = 0.003-1.2) and 1.5 nmol (95% CI = 0.4-128) for 
hNPW-23 and NPB-29, respectively. 
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4.4.2 Design of BBB-permeable Analogs of NPW   
To design NPW-derived compounds that can penetrate BBB, we explored the 
lipidization-cationization strategy previously employed to engineer BBB-permeable 
analogs of GAL, NT and NPY (GAL-B2, NT-BBB1, and NPY-BBB2, respectively) (10, 
20, 21, 30, 31). As illustrated in Figure 4.3, active fragments of these neuropeptides were 
used to introduce a lipoamino acid (Lysine-palmitoyl) in the context of several Lys 
residues, yielding the so called “lipidization-cationization” motif. These peptides potently 
suppressed seizures in mice following i.p. administration.  
For NPW, the following previously published SAR results were considered 
towards designing BBB-permeable analogs: (i) the C-terminal fragment NPW14-23 forms 
a distinct α-helix and is important for the activation of the NPBW1 receptor, and (ii) the 
N-terminal tripeptide of NPW is integral in discriminating between the two receptor 
subtypes (32). Kanesaka and coworkers constructed centrally-truncated analogs of NPW 
in which non-essential amino acid residues were replaced by backbone spacer units (5-
aminovaleric acid), resulting in potent and selective NPWB1 agonists (12).  The NPW 
analog containing three 5-aminovaleric acid units, namely NPW Ava-3 shown in Figure 
4.4, exhibited similar NPBW1 binding affinity to that of the full-length peptide (Ki 
(NPBW1)= 0.40 nM versus 0.14 nM).  As illustrated in Figure 4.4, the BBB-permeable 
analogs of NPW described here maintained the N-terminal “WYK” sequence and the C-
terminal active fragment while replacing central, non-essential amino acid residues with 
varying combinations of oligo-Lys motifs, lipoamino acid, and the 5-Ava spacer. Based 
on our previous experience with BBB-permeable galanin analogs, the position of the Lys- 





Figure 4.3 Examples of BBB-penetrating anticonvulsant neuropeptides modified by 
the lipidization-cationization motif.  Full-length amino acid sequences for GAL, NPY 
and NT are shown with bioactive fragments marked by boxed sequences. Bolded 
regions denote areas of increased positive charge.  (#) Represents C-terminal 






Figure 4.4 Design strategy for NPW-based analogs.  The primary sequence for hNPW-
23 is shown with bioactive fragments highlighted by boxed regions of the peptide.  
Based on previous SAR data, it was shown that centrally-truncated analogs of hNPW-
23 (NPW Ava-3) could be constructed that exhibited high affinity binding for NPBW1 
(12).  This work describes the synthesis and characterization of a series of centrally-
truncated NPW analogs which have been modified with the described lipidization-
cationization motifs.  Shown here is the analog NPW-B1 which was chosen as the lead 
candidate for further characterization. 
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 tests in mice (20). 
 
4.4.3 Chemical Synthesis   
All analogs were synthesized on solid support using an automated peptide 
synthesizer and standard Fmoc protocols.  Peptides were cleaved from resin by treatment 
with reagent K and were purified by preparative reversed-phase HPLC.   Peptides were 
quantified by measuring UV absorbance at 279.8 nm, then subsequently aliquoted and 
lyophilized by speedvac.  Masses of all compounds were confirmed by MALDI-TOF MS 
Retention times were calculated from the average of three independent HPLC separations 
for each analog and are summarized in Table 4.2. 
 
4.4.4. Partitioning Coefficient (logD) Results  
In our previous studies, we showed that application of the lipidization-
cationization strategy greatly increased partitioning coefficient values (logD) for 
truncated analogs of galanin (logD GAL-B2 = 1.2), neuropeptide Y (logD NPY-BBB2 
=1.8), and neurotensin (logD NT-BBB1 = 1.2) when compared to those of the native 
peptides (10, 20).  LogD-values for NPW analogs were determined using both the shake-
flask and HPLC capacity factor methods.  Calculated values for partitioning are 
summarized in Table 2.  The unmodified peptide hNPW-23 was rather hydrophilic 
evidenced by a negative logD value of -0.13, whereas the modified analogs showed 
dramatic increase in their hydrophobicity over the full length peptide with logD values 









































Ac-WYKK(Kp)KK(Ava)(Ava)GRAAGLLMGL# 1.5 ± 0.01* n.d. 
 
a(Kp) is Nε-palmitoyl-L-lysine, (Ava) is 5-aminovaleric acid, (#) represents C-terminal 
amidation.  bLogD values determined using the shake-flask method or based off of 
HPLC retention times.  *Denotes logD values determined using capacity factor (k') 
which was calculated by average retention HPLC time.  cHalf-life (t1/2) values were 
determined using an in vitro serum stability assay.  Peptides were incubated in 25% rat 
blood serum and degradation was monitored by analytical HPLC methods. 
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4.4.5 Metabolic Stability of NPW Analogs   
Our previous results showed significant improvement in the in vitro half-life (t1/2) 
values of modified analogs of galanin (t1/2 GAL-B2 > 9 h), neuropeptide Y (t1/2 NPY-
BBB2 > 3 h), and neurotensin (t1/2 NT-BBB1 > 2.7 h) in the rat serum stability assay (10, 
20).  To determine metabolic stability of NPW analogs, the peptides were incubated in 
25% rat blood serum at 37 °C and their degradation was monitored by HPLC. Aliquots 
were withdrawn after 30 min, 1 h, 2 h, 4 h, and 8 h and quenched with TCA followed by 
HPLC separations (20).  The time courses of the disappearance of the intact species were 
plotted and t1/2 values were calculated.  As summarized in Table 4.2 and Figure 4.6, in 
vitro metabolic stability was significantly increased. For the native peptide, the t1/2 value 
was 0.67 h, whereas the NPW-B1 had t1/2 of 3.6 h. Half-lives for the other selected NPW 
analogs were also increased, ranging from 1.5 – 3.7 h (Table 4.2; Figure 4.6).   
 
4.4.6. Antiseizure activity   
The antiepileptic activity of the analogs was evaluated in the 6 Hz model of 
epilepsy in mice following a bolus i.p. injection of 4 mg/kg. Protection from seizures was 
tested after 30 min post drug administration. As shown in Table 4.3, the unmodified 
NPW had no apparent antiepileptic activity, whereas NPW-B1, B2, B3, B5, and B7 
analogs exhibited 50% protection of the animals tested. NPW-B6 exhibited 75% 






Figure 4.5 Comparison of the relative hydrophobicities of hNPW-23 and NPW-B1.  
(A) HPLC traces showing the relative hydrophobicities of hNPW-23 versus NPW-B1.  
Conjugation of poly-Lys and Lys-P motifs resulted in analogs that were much more 
hydrophobic in nature.  Samples were analyzed by analytical HPLC over a linear 
gradient ranging from 5% to 95% Buffer B in 45 min.  All modified analogs exhibited 
similar shifts in retention times to that of NPW-B1.  (B)  Comparison of experimentally 
determined logD values for hNPW-23 and NPW-B1.  Values were calculated from the 
average of three independent experiments via the shake-flask method using a 50:50 
ratio of n-octanol/PBS, pH 7.4.  The amount of peptide in the aqueous phase was 
determined by the peak area using analytical HPLC over a gradient ranging from 5 to 
95% solvent B in 45 min.  LogD for the native peptide was calculated as -0.13; 
whereas, NPW-B1 had a logD value of 1.7. Statistical comparison between the full-
length and modified peptide was performed using the two-tailed t-test function of 





Figure 4.6 Comparison of metabolic stabilities of full-length hNPW-23 versus NPW-
B1. (A) Representative time course showing the degradation of NPW-B1 in the 
presence of 25% rat blood serum.  (B) Time-course experiments showing the time-
dependence of the disappearance on the intact peptide between 0 and 8 h.  Plot 
compares the degradation of hNPW-23 to that of NPW-B1.  Using the slope of the 
fitted line, half-lives (t1/2) were calculated as 0.67 and 3.6 h, respectively.  (C) 
Comparison of the calculated half-lives (t1/2) of hNPW-23 and NPW-B1 in the serum 
stability assay.  Results were obtained from the average slopes of three independent 
time-course experiments.  Statistical comparison was performed using the two-tailed t-
test function.  (**) P-value < 0.01. 
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Table 4.3. Summary of in vivo anticonvulsant activity for modified NPW analogs in 
the 6 Hz (32 mA) model of pharmacoresistant epilepsy. 
In vivo activity (4 mg/kg, i.p.) 



































6 Hz data were obtained from groups of four CF1 mice.  Data represent the number of 
mice within each group that did not exhibit classical seizure activity at the 30 min time 
point following i.p. administration of 4 mg/kg.  Motor toxicity values were determined 
using a rotorod motor impairment test (29). 
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To carry out dose response studies, NPW-B1 was selected. Figure 4.7 illustrates the dose-
response curve for the analog and the calculated ED50 data are summarized in Table 4.3. 
ED50 values, following i.p. administration, for NPW-B1 were calculated as 4.9 mg/kg 




Through the strategy of neuropeptide repositioning, this work describes the 
discovery of the anticonvulsant properties of NPW. Recent studies have shown a high 
level of expression of NPW and NPW-receptors in the hippocampus and amygdala of 
both rodents and humans, suggesting an important role for this peptide in the CNS (13, 
16, 33).  The peptides described in this work likely mediate their anticonvulsant activities 
through activation of the NPBW1 receptor as it has been previously shown that rodent 
models do not possess the NPBW2 subtype (34).  However, without detailed 
pharmacological studies, we cannot definitively exclude the possibility of off-target 
interactions with other GPCRs (noteworthy, the lipidization-cationization motifs applied 
here did not exhibit antiepileptic activities) (31).  It has been previously reported that 
activation of NPBW1 modulates hyperexcitability of neurons in the CNS (33).   Price and 
coworkers previously reported that application of NPW to neurons in the paraventricular 
nucleus of the hypothalamus resulted in a large population of hyperpolarized neurons 
(57%) with smaller mixed populations of depolarized and unchanged neurons (18).  We 
hypothesize that the observed anticonvulsant effects exerted by hNPW-23, and the 
modified NPW-analogs, resulted from activation of the NPBW1 receptor which may 
result in hyperpolarization of the cell membrane. Hyperpolarization of the membrane 





Figure 4.7 Dose-response curve for NPW-B1.  Mice were injected with 0.2, 2, 4, 6, 
and 8 mg/kg NPW-B1.  Peptide was administered i.p. into groups of eight adult male 
CF-1 mice (n = 4 for 0.2 and 8 mg/kg doses).  Data represent the percentage of animals 
which did not exhibit classical seizure-type behaviors at 30 min post administration 
(TPE).  ED50 for this analog was calculated as 4.9 mg/kg (95% CI = 2.9 – 12.2) using 
Probit software (24). 
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activity (1, 17).  This hypothesis remains to be tested and it is acknowledged that further 
studies into the precise mechanism by which NPW inhibits neuronal hyperexcitability 
need to be conducted. 
This work further extends the strategy of lipidization-cationization to improve 
CNS bioavailability of neuropeptides. Upon i.p. administration, hNPW-23 did not exhibit 
anticonvulsant activity suggesting that the native peptide does not reach its target in the 
brain. In the design of systemically-active NPW analogs, two structural elements were 
taken into account.  First, a positional scanning of the lipoamino acid relative to the C-
terminal active fragments of NPW was explored (NPW-B1 through NPW-B5).  All 
analogs exhibited similar anticonvulsant activities, suggesting that the positioning of the 
lipoamino acid is not crucial to the analogs’ anticonvulsant effects.  This is in contrast to 
our previous works which reported that placement of Lys-palmitoyl directly affected the 
biological activity of GAL analogs (20).    Second, the spacing between the N-terminal 
and C-terminal active fragments was examined through coupling of additional 5–Ava 
spacers (NPW-B6 and NPW-B7).  Interestingly, NPW-B6 produced the most protection 
in the screening assay (3/4 mice protected at the 30 min time-point), but this analog also 
exhibited the highest levels of motor impairment (4/4 mice affected) in the rotorod test. 
In our previous work, we observed that insertion of an additional Ala-residue into 
modified NPY analogs resulted in pronounced changes in anticonvulsant activities when 
compared NPY-BBB1 with NPY-BBB2 (10). In light of these differences, it does not go 
unnoticed that further optimization of NPW analogs should be undertaken as a part of the 
lead optimization studies.  It is conceivable that through the addition/deletion of 5-Ava 
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spacer units or introduction of other backbone spacers (9, 35), future NPW analogs may 
be designed that possess potent antiepileptic activity without exhibiting motor toxicity. 
BBB permeable analogs of NPW exhibited similar physicochemical and 
pharmacological properties to those previously observed in the modified GAL, NPY, and 
NT analogs (10, 20).  The insertion of Lys and Lys-palmitoyl residues to centrally-
truncated NPW resulted in increased logD and improved half-life in the rat serum 
stability assay.  The improvements to logD and metabolic stability were correlated with 
pronounced anticonvulsant activity in the 6 Hz mouse model of pharmacoresistant 
epilepsy following i.p. administration. The anticonvulsant activity of the systemically-
active NPW analogs is likely to be mediated by their native receptors in the brain. We 
show in our previous work, that the combination of the lipidization and cationization did 
not affect affinities of the GAL, NPY or NT to their respective native receptors (10, 20, 
21, 30). Thus, based on SAR results for centrally-truncated NPW analogs (12), NPW-B1 
to B7 are expected to retain similar affinities towards NPBW1 receptors. We 
acknowledge here that more pharmacological studies are needed, both in vitro and in 
vivo, to dissect the exact mechanism of seizure control by BBB-permeable analogs of 
NPW. 
The lipidization-cationization strategy sets out to overcome the issues of 
metabolic instability and poor bioavailability of neuropeptides. The development of 
systemically-active NPW analogs further increases the number of anticonvulsant 
neuropeptides that can be explored as CNS-acting neurotherapeutics. As alluded to 
earlier, NPW has garnered recent interest because of its ability to regulate feeding 
behaviors and influence metabolic function (36-38).  It was previously reported that 
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NPW accomplishes these roles through activation of NPW-receptors in the 
hypothalamus.  It has been hypothesized that NPW acts through a compensatory 
mechanism to regulate energy homeostasis when leptin levels in the brain are decreased 
(37).  Therefore, the modified NPW analogs described here may be useful 
pharmacological compounds towards the development of therapies for metabolic 
illnesses leading to obesity. In summary, the combination of rational repositioning and 
peptide engineering has provided new tools to study a role of NPW in the brain.  
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INTRODUCTION OF LIPIDIZATION-CATIONIZATION MOTIFS  
INTO CYCLIC PEPTIDES: DESIGN, SYNTHESIS  






 Anticonvulsant neuropeptides play an important role in controlling neuronal 
excitability that leads to pain or seizures. Based on overlapping inhibitory mechanisms, 
many anticonvulsant compounds have been found to exhibit both analgesic and 
antiepileptic activities. An analgesic neuropeptide W (NPW) targets recently 
deorphanized G-protein coupled receptors. Here, we tested the hypothesis that the 
analgesic activity of NPW may lead to the discovery of its antiepileptic properties. 
Indeed, direct administration of NPW into the brain potently reduced seizures in mice. To 
confirm this discovery, we rationally designed, synthesized and characterized NPW 
analogs that exhibited anticonvulsant activities following systemic administration. Our 
results suggest that the combination of neuropeptide repositioning and engineering NPW 
analogs that penetrate the blood-brain barrier could provide new drug leads, not only for
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the treatment of epilepsy and pain, but also for studying effects of this peptide on 
regulating feeding and energy metabolism coupled to brain levels of leptin.  
 
5.2 Introduction 
5.2.1 Application of the Lipidization-cationization Strategy  
to Conformationally-constrained Cyclic Peptides 
Previous efforts have focused on conjugation of the lipidization-cationization 
motifs to the N- or C-termini of unstructured, linear peptides (GAL, NT, NPY, and 
NPW).  These efforts revealed that this strategy was effective independent of the primary 
amino acid sequence or the point of attachment of the modification (N- or C-termini). 
This chapter will discuss the application of such modifications to short, conformationally-
constrained cyclic peptides containing a single disulfide bridge.  Formation of the 
disulfide bridge confers a level of rigidity to cyclic peptides.  Cyclic peptides comprise a 
large and varied class of naturally-occurring and synthetically-derived compounds.  
Many of these peptides exhibit increased metabolic stability, receptor specificity, and 
increased biological activity (1).  Five general topologies exist within cyclic peptides 
(Figure 5.1).   
This chapter will focus on the modification of two peptides, somatostatin and 
erythropoietin mimetic peptide (EMP), that contain side-chain to side-chain cyclization 
through the formation of a single disulfide bridge.  Emphasis will be placed on cyclic 
peptides that are conformationally-constrained through side-chain to side-chain 
cyclization; however, it should also be noted that peptides possessing other cyclization 







Figure 5.1.  Schematic representations of different topologies exhibited by cyclized 
peptides.  Figure was adapted Sewald and Jakubke (1). 
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5.2.2 Somatostatin and Erythropoietin 
Somatostatin (SOM) was initially identified as a regulatory compound, inhibiting 
the release of certain hormones.  Recently, somatostatin and somatostatin analogs have 
shown promise as analgesics, anticonvulsants and as anti-proliferative compounds (2-4).  
Both variants (SOM-14 and SOM-28) have been shown to exhibit similar biological 
effects, serving as high affinity ligands for their GPCR targets. SOM binds to one of five 
somatostatin receptor subtypes (sst1-sst5) (5).  The sst2 and sst4 receptor subtypes have 
been implicated in controlling seizure activity in rodent models (6).  In efforts to discover 
the minimal number of residues required to elicit a biological effect, structure-activity 
studies were carried out.  Through these efforts, the SRIF analog octreotide (Oct) was 
discovered.  It was found that a minimal structure consisting of eight residues, 
constrained by a single disulfide bridge, exhibited increased metabolic stability, increased 
biological activity, and prolonged action (7).  Moreover, octreotide was found to be 
selective for the sst2-receptor subtype (8).  Despite the improvements conferred by 
octreotide over somatostatin, it was hypothesized in this work that modification of the 
octreotide framework would result in metabolically-stable, BBB-permeable analogs of 
somatostatin.   
 The idea of hormone-mediated regulation of red blood cell production has been 
known since the early 1900’s.  However, it was not until 1985 that the gene encoding this 
protein, erythropoietin (EPO), was first isolated and characterized (9).  The initial role of 
this 166 amino acid glycoprotein (34 kDa) was found to be regulation of proliferation and 
differentiation of red blood cells (10, 11).  More recently, a role for this protein in the 
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central nervous system as a neurotrophic factor and in controlling seizure activity was 
identified (12, 13).   
Recently, peptide minimized analogs have been identified which could be 
chemically-synthesized and modified using solid phase peptide synthesis.  In an attempt 
to develop multimeric EMPs, Vadas and co-workers developed both N- and C-terminally 
modified peptides (10).  Using the N-EMP and C-EMP analogs as a template, we 
designed and synthesized a series of analogs possessing the lipidization-cationization 
motifs at both the N- and C-termini of erythropoietin mimetic peptides. 
 
5.3 Materials and Methods 
5.3.1 Design of Somatostatin and Erythropoietin Analogs  
Containing Lipidization-Cationization Motifs 
 As mentioned earlier, octreotide was found to exhibit similar/improved 
physicochemical and pharmacological properties to those of SOM-14 and SOM-28 (7).  
Octreotide is essentially the C-terminal fragment of full-length SOM; it was therefore 
assumed that insertion of the lipidization-cationization motif at the N-terminus of 
octreotide would not interfere with receptor binding or activation.  Furthermore, it has 
been previously reported that N-terminal glycosylation, PEGylation and lipidization of 
somatostatin analogs afforded ligands with comparable, or even increased, affinity for 
sst2-receptors (14-16). Based on this information, a series of somatostatin analogs were 
designed that incorporated lipidization-cationization motifs attached to the N-terminus of 
octreotide.  The somatostatin analog SOM-BBB1 (KKKpK-Oct-NH2) directly coupled the 
lipidization-cationization motif to the N-terminus of octreotide. This arrangement of three 
 118
Lys-residues and Nε-palmitoyl-L-lysine was determined as the optimal lipidization-
cationization motif for systemically-bioavailable galanin analogs (17). SOM-BBB2 
(KKKpG-Oct-NH2) was designed to test the degree to which cationic character influenced 
biological activity of somatostatin analogs.  This was accomplished by the [K4G] 
substitution, which effectively lowered the cationic character of this analog.  SOM-BBB3 
(KKKp(Ahx)-Oct-NH2)  was designed to test whether increased distance between the 
lipidization-cationization motif and the bioactive fragment improved or attenuated 
pharmacological activity.  SOM-BBB4 (KKKp(Ahx)G-Oct-NH2) maintained the spacing 
motif described for SOM-BBB3, but effectively switched the positioning of the palmitoyl 
motif relative to the peptide backbone.  Our previous efforts with neuropeptide Y showed 
that insertion of an additional Ala-residue could have dramatic effects on the biological 
activity of the modified analogs (18).  In SOM-BBB5, incorporation of polar PEG-type 
spacers was explored perhaps giving rise to somatostatin analogs that are active on 
peripheral neurons for the treatment of neuropathic pain (Figure 5.2). 
Using peptide sequences obtained from phagemid mutagenesis libraries collected 
and screened by Wrighton and co-workers, a number of EMPs have been identified that 
exhibit similar physicochemical and pharmacological properties to that of the full-length 
protein (10, 19). Johnson and coworkers showed that EMP analogs N-terminally 
conjugated with PEG motifs could bind to erythropoietin receptors (EPOR) with 
micromolar affinities (20). Furthermore, in an attempt to construct multimeric analogs of 
EMPs, Vadas recently showed that modifications could be made to either the N- or C-






Figure 5.2 Design strategy for somatostatin analogs containing lipidization-
cationization motifs.  Using octreotide as a scaffold, five analogs were designed.  
Analogs were designed that explored the consequences of increased/decreased cationic 
character, increased distance between the bioactive fragment and lipidization-
cationization motifs, positioning of the lipoamino acid relative to the peptide backbone, 
and incorporation of polar PEG-type spacers. 
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these compounds can accommodate modifications at either terminus, we designed a 
series of erythropoietin analogs that contained lipidization-cationization motifs coupled 
directly to either the N- or C-terminus (EPO-BBB1 and EPO-BBB3).  Additionally, the 
distancing and positioning of the lipoamino acid, with respect to the peptide backbone, 
was examined through insertion of a single Gly-residue between the lipidization-
cationization motif and the EMP scaffold (EPO-BBB2 and EPO-BBB3) (Figure 5.3). 
 
5.3.2 Solid Phase Peptide Synthesis 
 Synthesis of somatostation and erythropoietin analogs was carried out using a 
Symphony automated peptide synthesizer (Protein Technologies, Inc).  Syntheses were 
carried out at 50 μmol scale using preloaded Amide-AM resins.  Triple couplings of each 
amino acid (30, 30, and 40 min) were performed using 0.2 M PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate), 0.4 M DIPEA (N,N-
diisopropylethylamine), and 200 mM of each amino acid.  Protected amino acids, 
including Fmoc-Lys(palmitoyl) and Fmoc-protected spacers were obtained commercially 
from Chem-Impex International.  Peptides were cleaved from resin by treatment with 
reagent K (82.5% TFA, 5% water, 5% ethanedithiol, 2.5% thioanisole v/v, 75 mg/mL 
phenol) followed by vacuum filtration to separate peptide from resin, and finally 
precipitated with chilled methyl-tert-butyl ether.  Crude peptides were then purified by 
preparative reversed-phase HPLC over a linear gradient of solvent B (90% acetonitrile in 
0.1% TFA).  Purities of separated fractions were assessed by analytical reversed-phase 







Figure 5.3 Design strategy for erythropoietin analogs containing lipidization-
cationization motifs.  Using an EMP scaffold described by Wrighton, erythropoietin 
analogs were designed that contained lipidization-cationization motifs at either the N- 
or C-termini.  Consequences of the spacing/position of the modifications, relative to 
the bioactive fragment were explored through insertion of an additional Gly residue 





than 95% were pooled and quantified by measuring UV absorbance at either 279.8 nm 
(SOM) or 274.6 (EPO).  Molecular masses of all linear peptides were confirmed by 
MALDI-TOF MS. 
 
5.3.3 Oxidation of Modified Somatostatin and Erythropoietin Analogs 
 Disulfide bond formation in somatostatin analogs was accomplished through 
oxidation of the linear peptide using CLEAR-OXTM resin (21, 22).  Briefly, resin was 
prepared as described previously (22).  Linear peptide was then reconstituted in 0.1 M 
Tris-HCl, pH 7.0 and was added to the pre-swelled resin.  Peptides were incubated at 2 h 
at room temperature; after which, the oxidized peptide was removed from resin by 
vacuum-filtration.  Completion of the oxidation reaction was verified by analytical 
reversed-phase HPLC and was confirmed by MALDI-TOF mass spectrometry. 
 Initial efforts to form the disulfide bridge in EPO analogs using CLEAR-OX resin 
were unsuccessful.  EPO analogs were oxidized in solution in a manner similar to that 
described by Nielsen and coworkers (23).  Briefly, linear peptide was reconstituted in 
nH2O.  Peptide was then added, at a final concentration of 20 μM, to a solution 
containing 30% acetonitrile, 0.1 mM GSSG, and 0.1 M Tris-HCl, pH 7.4.  Oxidation was 
allowed to proceed for 6 h at room temperature.  Reactions were quenched with formic 
acid (8% of total reaction volume) and peptides were purified by preparative reverse-
phased HPLC using a linear gradient ranging from 5% to 95% solvent B in 30 min.  
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Following HPLC purification individual fractions were purified, pooled and masses of 
the folded peptides were confirmed by MALDI-TOF mass spectrometry. 
 
5.4 Results and Discussion 
 Analogs of the cyclic peptides somatostatin and erythropoietin were synthesized 
using solid phase peptide synthesis.  Following synthesis, peptides were cleaved from 
resin by treatment with reagent K, and were purified by analytical HPLC.  Final yields of 
the purified linear peptides ranged between 8-10%, with respect to resin mass, for both 
SOM and EPO analogs.  Somatostatin analogs were oxidized using the solid-support 
CLEAR-OX.  Final yields of the modified somatostatin analogs ranged between 40 and 
62.5% of correctly oxidized peptide.  Conversely, using solution oxidation methods, 
nearly all of the purified linear EPO analogs was recovered as the completely oxidized 
peptide.  Following HPLC purification of the oxidized peptides, MALDI-TOF mass 
spectrometry analysis was conducted to verify formation of the disulfide bridge.  All 
analogs were observed to possess masses 2 Da lower than those of their linear 
counterparts, indicating disulfide bridge formation (Figure 5.4). 
 
5.5  Conclusions 
 As illustrated here, lipidization-cationization motifs were applied to short, 
conformationally-constrained analogs of the cyclic peptides somatostatin and 
erythropoietin.  These compounds were synthesized by solid phase peptide synthesis and 
disulfide bridge formation was accomplished by oxidation using both solution and solid 





Figure 5.4 Oxidation of cyclic peptides containing lipidization-cationization motifs.  
Panel A illustrates representative HPLC traces of the somatostatin analog SOM-BBB3.  
In addition to differences in HPLC retention time, a decrease in mass was observed by 
MALDI-TOF.  Panel B shows representative HPLC traces for oxidation of the EPO 




 Subsequent studies will focus on physicochemical and pharmacological 
characterization of the modified SOM and EPO analogs.  For example, somatostatin is 
generally considered to possess poor systemic bioavailability.  However, octreotide 
exhibited increased BBB-permeability, though it was still found to cross the BBB by 
passive diffusion and only at rates similar to those of albumin (24).   Octreotide was also 
shown to possess increased serum half-life, t1/2(SOM-14) < 3 min versus t1/2(octreotide) = 
1.5 h (25).  It is anticipated, based on our previous findings, that these values may be 
further improved.  Moreover, it is expected that lipidization-cationization motifs applied 
to the octreotide framework may result in systemically-active peptide analogs in mouse 
models of epilepsy.  Likewise, it is recognized that further characterization of the EPO 
analogs must be undertaken to show improved characteristics of these compounds in 
comparison to existing EMPs.  Efforts to determine the metabolic stabilities and logD 
values for SOM and EPO analogs are ongoing in an attempt to engineer analogs with 
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This work describes the first examples of peptidic ligands of GAL, NPY, and 
NPW that penetrate the BBB and are active in suppressing seizure activity following 
systemic administration.  To overcome the issues that have traditionally precluded the 
development of peptide-based drugs (i.e., poor metabolic stability and low 
bioavailability), our lab successfully employed a novel strategy of the combination of 
lipidization and cationization towards the development of metabolically-stable, 
systemically-bioavailable analogs of galanin, neurotensin, neuropeptide Y, and 
neuropeptide W for the treatment of neuropathic pain and epilepsy.  This work serves as 
proof-of-concept that through modification of the bioactive fragments of endogenous 
neuropeptides, receptor-specific peptide ligands with improved physicochemical and 
pharmacological characteristics could be constructed.  Furthermore, we have found that 
through these modifications, analogs could be modified for specific targeting of their 
receptors in the CNS or PNS.    
As illustrated in Figure 6.1, the strategy described in this thesis has broader 




Figure 6.1  Potential outcomes/directions of the lipidization-cationization strategy. 
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First, using combinations of lipidization-cationization motifs, biologically-active 
peptides, can be modified to construct peptide-based therapeutics for a number of non-
neurological disorders.  Second, BBB-permeable neuropeptides could be used as tools for 
the study or treatment of the long-term effects of pain or epilepsy (synaptic 
neuroplasticity).  Third, our work encourages an in-depth look at the combination of 
existing BBB-penetration strategies in an attempt to develop new peptide analogs with 
increased bioavailability.    Fourth, extension of this technology to peptidic compounds 
such as non-ribosomal peptide (NRP) and ribosomal peptide (RP) natural products may 
result in the development of potent antimicrobial or anticancer drugs with improved 
bioavailabilty for the treatment of infections of the CNS or certain brain cancers.   
Finally, using BBB-permeable analogs containing labeling motifs (e.g., fluorescent 
labels, radiolabels, IR probes, etc.), may yield new tools for imaging regions/receptors in 
the brain that possess increased specificity for their CNS targets. 
 
6.1.1 Drugs for Other Indications  
There currently exists a great potential for the development of peptide-based 
drugs capable of specifically targeting receptors throughout the body for the treatment of 
a wide variety of human illnesses.  As mentioned earlier, many GPCR targets of 
neuropeptides are expressed in tissues of both the CNS and PNS.  Furthermore, many of 
these receptors are multifaceted in their biological function depending on their location.  
This is of particular interest in the development of peptide ligands for receptors 
implicated in non-neurological disorders.  In addition to their roles as neuromodulatory
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compounds, neuropeptides such as galanin, neuropeptide Y, and neuropeptide W have 
been also studied for their orexigenic (modulation of food intake) effects; modulated 
through receptors in other locations within the brain (1, 2).  It is conceivable that through 
specific targeting of peptide analogs to the receptors that modulate orexigenesis, first-in-
class treatments for disorders such as obesity, or even diabetes, could be developed.  
Moreover, we have previously shown that modifications made to the lipidization motif 
itself (i.e., altered chain length or PEGylation) could direct peptide analogs to receptors in 
the peripheral nervous system (3). This is of particular interest in the specific targeting of 
analgesic peptides such as opioid peptides, substance P, and neuropeptide FF to receptors 
in peripheral neurons (Table 6.1).  Towards the development of peripherally-acting 
neuropeptides, special care must be taken to avoid unintended delivery to the CNS.  In 
doing so, one avoids many of the adverse side effects that might result from interactions 
of these analgesic neuropeptides with their respective receptors in the brain (e.g., 
drowsiness, decreased cognitive function, respiratory depression, etc.).     
 
6.1.2 Modulators of Neuroplasticity  
Another promising outcome of this research may be in the development of new 
pharmacological tools to aid in studying synaptic plasticity of the nervous system (10).  
As a result of extended periods of neuropathic pain or seizure, expression of certain 
neuropeptides is altered (11).  Expression levels of important anticonvulsant peptides 
(galanin, neuropeptide Y, etc.) are decreased; whereas de novo synthesis of 
proconvulsant neuropeptides (neurokinin B and substance P) is increased (11).  The 
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Table 1.  Examples of endogenous neuropeptides that may be modified for improved 
analgesic effect. 
 












Substance P RPKQQFFGLM# 
 
Neurokinin receptor 
subtype 1 (NK1R) 
 
(6) 
Neuropeptide FF FLFQPQRF# 
 















Selected endogenous peptides that may be modified to target peripheral neurons for 
antinociceptive effect.  (^) denotes a carboxylated C-terminus; (#) denotes C-terminal 
amidation.  Through attachment of lipidization-cationization motifs to the minimal 
number of residues necessary to elicit the peptides’ biological effect, novel peptide-




maladaptive restructuring of proconvulsant and anticonvulsant peptides results in the 
inability of neuronal tissues to properly regulate excitatory/inhibitory behaviors (12).  
This often leads to persistent seizure activity or chronic pain states.  Systemic 
administration of BBB-permeable anticonvulsant compounds could potentially 
compensate for the loss of important neuromodulatory compounds such as galanin, 
neuropeptide Y, and others.  Moreover, BBB-permeable analogs may be explored for 
their disease modification properties.  Through administration of the modified peptides, 
researchers could effectively alter the expression levels of other endogenous 
neuropeptides in the brain.  With respect to neurological disorders such as pain or 
epilepsy, this could prove of great worth as a treatment that actually reverses the effects 
of such disorders. 
 
6.1.3 Continued Research on Design of BBB-penetration Strategies  
This research also encourages further exploration into alternative combination 
strategies for the development of CNS targeting peptides.  Numerous strategies have been 
employed to increase serum stability and bioavailability of peptide-based drugs.  All of 
the listed BBB-penetration strategies were shown to increase metabolic stability of the 
peptides; however, the effects of these modifications on logD values, as an indicator of 
the lipophilicity of the compounds, were varied (13, 14).  It is therefore conceivable that 
any number of the aforementioned strategies could be employed simultaneously to 
increase serum stability, providing receptor binding/activation was not adversely 
affected.  However, certain combinations of these strategies may lead to more 
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pronounced changes in logD values, and subsequent BBB-penetration of the modified 
peptides.   
This work described the combination of lipidization and cationization for 
improved BBB-penetration.  Based on our research, increased lipophilicity appears to be 
the major contributor for increased BBB-penetration.  This modification likely increased 
BBB-penetration via passive diffusion as a direct result of increased lipophilicity of the 
peptide.  Whereas, increased cationic character, in the context of oligo-Lys motifs, may 
have facilitated BBB-penetration through absorptive mediated endocytosis (15).  
However, we also showed that increased lipophilicity or increased cationic character 
alone did not facilitate efficient delivery of analogs into the brain (see Chapter 1); rather, 
the combination of these two modifications was required for systemic bioavailability 
(16).  Liu and coworkers described the combination of increased N-terminal cationization 
and halogenation of endomorphin-1 for increased bioavailability (13).  By itself, 
cationization actually decreases the overall lipophilicity of peptide drugs. However, in 
agreement with our findings, the combination of this chemical modification with a 
modification that increases lipophilic character (halogenation) resulted in endomorphin 
analogs with increased metabolic stability and improved BBB-penetration (13).   
Based on the individual effects of each modification on logD, and overall BBB-
permeability, it is hypothesized that increased lipophilicity is the primary contributor to 
increased BBB-penetration.  As such, the conjugation of lipidization or halogenation 
(through addition of Cl or Br groups) motifs may have the greatest effects on CNS 
delivery.  However, the combination of multiple strategies that increase lipophilicity is 
not likely viable due to decreased solubility and serum stability of the peptide analogs.  
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By combining these modifications with others that do not significantly contribute to 
peptide lipophilicity (glycosylation, cationization, or polymer conjugation), analogs may 
be designed that are capable of exploiting both active and passive transport mechanisms.  
Furthermore, it is conceivable that the combination of two, or more, strategies that do not 
increase logD values (cationization, glycosylation, or polymer conjugation) may prove 
effective in the construction of peptides that act specifically on the periphery.  In 
conjunction with the lipidization-cationization strategy described in this work, Liu’s work 
served as evidence that the combination of two or more of these strategies may be 
effective in developing peptide-based drugs for treatment of numerous indications both 
centrally and peripherially (Table 6.2). 
 
6.1.4 Antibiotic and Anticancer Drugs   
The lipidization-cationization strategy may not be entirely limited to endogenous 
neuropeptides.  Recent interest has been drawn by the therapeutic potentials of peptidic 
compounds such as the non-ribosomal peptide (NRP) and ribosomal peptide (RP) natural 
products (21, 22).  Many of these compounds have shown tremendous potential as 
therapeutics due to their antimicrobial or anticancer properties; unfortunately, a large 
number also possess poor systemic bioavailablity (i.e., vancomycin) (23).  Furthermore, 
NRP and RP natural products isolated from fungi or bacteria exhibit a large structural 
diversity, providing a large repertoire of peptide scaffolds from which novel peptide-
based therapeutics could be generated.    Using available structure-activity information 
for these compounds, lipidization-cationization motifs could be rationally-incorporated  
 
 137
Table 6.2  Strategies for improving CNS delivery of peptides. 
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Table presents numerous strategies for increasing the BBB-permeability of peptide-
based drugs.  The effects of each modification on serum stability, lipophilicity (logD), 
and overall BBB-permeability are listed.  This work explores the combination of two 
strategies for development of systemically-bioavailable neuropeptides.  Based on our 




towards the synthesis of NRP or RP natural product analogs with improved 
bioavailability.  As a result BBB-permeable NRP/RP analogs could be constructed as 
first-in-class treatments for bacterial infections of the CNS like bacterial meningitis or 
bacterial encephalitis, or as treatments of neuroblastomas. 
 
6.1.5 Imaging Tools  
Another application of the lipidization-cationization strategy is the development 
of peptide-based imaging tools specifically targeted to the CNS.  Recently, much effort 
has been devoted towards the creation of receptor-specific molecular probes for the 
imaging of tumors.  Both radiolabeled and fluorescently-labeled analogs of neurotensin 
have been developed for diagnosis/imaging of tumors in the peripheral tissues; largely 
facilitated by the increased expression of neurotensin receptors on the surface of 
cancerous cells (24, 25).  By engineering fluorescently-labeled peptide analogs that cross 
the BBB, peptide-based labeling systems may prove useful in specifically 
targeting/identifying neuropeptide receptor subtypes in the brain or spinal chord.  
Furthermore, BBB-permeable neuropeptide probes might also be used as contrasting 
agents for real-time imaging of brain tissues.   This application would further compliment 
previous efforts with NT and NPW, while spurring further efforts towards developing 
Gal, NPW, SOM, etc. as imaging tools. 
 
6.2 Conclusions 
In summary of this section, the lipidization-cationization strategy was found 
broadly applicable across numerous endogenous neuropeptides (GAL, NT, NPY, and 
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NPW). This combination strategy resulted in multiple systemically-bioavailable peptide 
analogs (Gal-B2, NT-BBB1, NPY-BBB2, and NPW-B1) that were shown active in 
suppressing seizures in the 6 Hz psychomotor seizure model in mice.  The anticonvulsant 
properties of these analogs were directly attributed to the improved metabolic stability 
and increased logD values, conferred by the lipidization-cationization motifs.  It was also 
shown in previous sections that this approach could be further applied towards the 
synthesis and preparation of analogs of cyclic peptides such as somatostation or 
erythropoietin.  Lastly, this chapter has illuminated the larger potential of the lipidization-
cationization strategy for the construction of peptide-based tools for the study and/or 
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